Ready has now surpassed more than 25 million essential learning behaviors informing its predictive performance models.
These models have enabled more than 50 pharmaceutical companies, biotechs, clinical research organizations, and healthcare systems to deliver more efficient clinical trials and better care for millions of patients.
Increasing trial complexity leads to more errors and delays. So who bears the burden? Sites.
Watch this recorded webinar, as we discuss real clinical trial examples from emerging biotechs that will give you techniques to transform and improve the study start up — and reduce site burden.
ValenzaBio, a biotech focused on developing monoclonal antibody therapeutics for autoimmune and inflammatory indications, selected Ready to re-imagine site initiation and optimize trial team performance on its Phase II study.
Our clinical trial pre-startup risk assessment measures your study against four predictive indicators of clinical trial team readiness and performance risk to reveal specific areas you can proactively address during study planning and site initiation to accelerate timelines and avoid preventable delays.
21 of the top 25 Pharmaceutical firms, emerging biotechs, and leading healthcare organizations relied on Ready in 2021.
Over 200,000 clinicians and life science professionals have increased their knowledge and improved performance with ArcheMedX.
Learn how Ready enhances your ability to accelerate study startup and improve overall trial team performance by identifying risks sooner and tailoring more effective training around the most critical areas of your study.